This study is conducted in Asia, Europe and North America. The aim of this observational study is to evaluate the safety of NovoPen Echo® by collecting safety information (incidence of technical complaints related to adverse reactions). Study duration: 12-18 weeks.

Inclusion Criteria:

• Children/adolescents with type 1 diabetes mellitus
• After the participating physician's decision has been made to initiate treatment with NovoPen Echo®, any patient who meets all the inclusion criteria and does not meet any of the exclusion criteria, is eligible to participate
• Use of insulin pen or syringes for at least 12 months

Exclusion Criteria:

• Insulin pump or Insuflon® users
• Any disease or condition in children/adolescents which might interfere with the study at the individual physician's discretion

Any child or adolescent with type 1 diabetes who has just started using NovoPen Echo® is eligible. The selection of the patients will be at discretion of the individual physician.